AYTU vs CTAS · rev $66.4M vs P/E 51, rev $11.26B
Aytu BioScience Inc (AYTU) versus Cintas Corporation (CTAS) — a side-by-side from cached financials, not a winner call.
Aytu BioScience Inc (AYTU) is a drug manufacturers - specialty & generic company listed on US.
Cintas Corporation (CTAS) is a specialty business services company listed on US.
Latest reported AYTU revenue for 2025-06-30 was $66.4M. Net income was -$13.6M. AYTU currently screens at market cap $24.1M.
Latest reported CTAS revenue for 2026-05-31 was $11.26B. Net income was $2.00B. Revenue was up 8.9% from 2025-05-31 to 2026-05-31. CTAS currently screens at market cap $89.01B and trailing P/E 51.3.
AYTU currently screens at market cap $24.1M. CTAS currently screens at market cap $89.01B and trailing P/E 51.3.
Not investment advice. Open the AYTU and CTAS stock pages for the full models.
Not investment advice.